Cystic fibrosis gene therapy - GSK/Valentis
Alternative Names: GR 213487B; MB121Latest Information Update: 02 Jul 2023
At a glance
- Originator GlaxoSmithKline
- Developer Valentis
- Class Gene therapies
- Mechanism of Action Cystic fibrosis transmembrane conductance regulator stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Cystic fibrosis
Most Recent Events
- 21 Mar 2001 Discontinued-II for Cystic fibrosis in USA (Intranasal)
- 23 Jan 2001 Glaxo Wellcome has merged with SmithKline Beecham to form GlaxoSmithKline
- 22 Jun 1999 The Megabios/GeneMedicine merged company is now called Valentis